5. Conclusions
allergy-associated, allergy, atopic dermatitis, CMPA
ALLERGY, ATOPIC DERMATITIS
The data from our study support that infants at high risk for allergy who are not exclusively breastfed, benefit with regards to allergy-associated outcomes, when supplemented with a specific whey-based pHF complementary to breastfeeding compared to mixed-feeding with a standard formula of intact protein. Supplementation of the studied pHF to BM resulted in reduced incidence of atopic dermatitis and CMPA, particularly in those high risk for allergy infants with a family history of atopic dermatitis. The growth outcomes of study participants during the first 6 months of life were within the normal range in all feeding regimens. The findings of the A.R.T. study suggest the use of this specific whey-based pHF in mixed-fed infants for the prevention of allergy outcomes within the first six months of life.